SeekingAlpha · Aug 16, 2026
NYSE · RVTY
Revvity, Inc.
Healthcare · Medical - Diagnostics & Research
$128.67
Down-$0.13 (-0.10%)
Updated Sep 1, 2026, 10:44 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 12.32B
- P/E ratio
- 51.31
- Dividend yield
- 0.27%
- 52-week range
- $81.22 – $130.07
- Volume
- 1.63M
- Avg. volume
- 1.43M
Price performance
RVTY price history
1M range · 21 trading sessions · Daily adjusted prices
RVTY closed at $128.67 after 21 trading sessions, up 11.67% for the selected period.
- Last close
- $128.67
- Period change
- +11.67%
- Period low
- $111.39
- Period high
- $129.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $127.34 | $128.815 | $125.456 | $128.67 | 1.63M |
| Aug 28, 2026 | $128.57 | $130.07 | $127.26 | $128.80 | 1.58M |
| Aug 27, 2026 | $126.53 | $129.80 | $126.50 | $129.71 | 1.93M |
| Aug 26, 2026 | $123.29 | $126.90 | $123.29 | $126.35 | 1.16M |
| Aug 25, 2026 | $123.69 | $124.94 | $122.0109 | $124.84 | 1.04M |
| Aug 24, 2026 | $123.49 | $124.89 | $121.38 | $123.00 | 1.51M |
| Aug 21, 2026 | $124.48 | $124.97 | $121.51 | $124.75 | 2.29M |
| Aug 20, 2026 | $118.26 | $124.49 | $116.955 | $124.13 | 2.34M |
| Aug 19, 2026 | $116.02 | $122.11 | $115.29 | $119.45 | 1.72M |
| Aug 18, 2026 | $115.86 | $115.90 | $113.69 | $113.75 | 800.03K |
| Aug 17, 2026 | $115.97 | $117.25 | $115.97 | $116.17 | 786.67K |
| Aug 14, 2026 | $116.51 | $117.72 | $115.66 | $116.84 | 774.56K |
| Aug 13, 2026 | $118.25 | $118.34 | $115.67 | $117.50 | 1.37M |
| Aug 12, 2026 | $115.21 | $117.94 | $114.64 | $117.88 | 1.21M |
| Aug 11, 2026 | $115.83 | $116.84 | $115.095 | $115.73 | 1.29M |
| Aug 10, 2026 | $114.22 | $116.74 | $112.68 | $116.02 | 1.25M |
| Aug 7, 2026 | $114.98 | $115.51 | $113.735 | $114.66 | 1.03M |
| Aug 6, 2026 | $114.24 | $115.00 | $112.24 | $114.24 | 1.26M |
| Aug 5, 2026 | $112.45 | $115.84 | $110.81 | $115.02 | 2.15M |
| Aug 4, 2026 | $114.50 | $117.37 | $107.73 | $111.39 | 2.59M |
| Aug 3, 2026 | $112.48 | $116.32 | $112.15 | $115.22 | 2.59M |
Latest RVTY news
The latest Smart Investors Daily articles mentioning RVTY.
Stock researchCompany · Overview
RVTY research
Overview
Company profile and research snapshot.
Company profile
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $110.25
- Implied upside
- —
- Analysts
- 25
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Bernstein | Market Perform | — |
| May 7, 2026 | Barclays | Equal-Weight | — |
| May 6, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 14, 2026
Danaher: 2027 Growth Reacceleration Should Drive Upside
Yahoo · Aug 13, 2026
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Yahoo · Aug 13, 2026
The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
